布地奈德福莫特罗粉吸入剂联合孟鲁司特钠对咳嗽变异性哮喘的肺功能及血浆hs-CRP影响  

Effect of budesonide and formoterol fumarate powder for inhalation combined with montelukast on lung function and hypersensitive C-reactive protein in patients with plasma of cough variant asthma

作　　者：叶军盼 戴建国[1] 赵委阳 何云霄[3] 潘志杰[4] YE Junpan;DAI Jianguo;ZHAO Weiyang(Department of Respiration,Tiantai Traditional Chinese Medical Hospital,Tiantai 317200,China)

机构地区：[1]天台县中医院呼吸科,浙江天台317200 [2]天台县中医院肺功能室,浙江天台317200 [3]天台县中医院检验科,浙江天台317200 [4]浙江大学医学院附属第一医院呼吸科

出　　处：《全科医学临床与教育》2019年第4期326-328,共3页Clinical Education of General Practice

摘　　要：目的探讨布地奈德福莫特罗粉吸入剂联合孟鲁司特钠对咳嗽变异性哮喘(CVA)的肺功能及血浆超敏-C反应蛋白(hs-CRP)影响研究。方法选取106例CVA患者随机分为观察组和对照组。两组均予以布地奈德福莫特罗粉吸入剂治疗,观察组加用孟鲁司特钠片治疗,疗程2个月。比较两组治疗前后肺功能及hs-CRP指标变化,治疗效果及不良反应。结果治疗2个月后,两组一秒用力呼气容积(FEV_1)、用力呼气肺活量(FVC)、呼气峰值(PEF)指标均较治疗前明显升高,血浆hs-CRP指标明显下降(t分别=2.34、2.40、2.36、3.01、3.27、3.35、2.45、3.47,P均<0.05)。且观察组治疗后FEV_1、FVC、PEF较对照组更高,血浆hs-CRP更低(t分别=2.27、2.31、2.37、2.24,P均<0.05)。观察组总有效率高于对照组(χ~2=6.01,P<0.05),但两组不良反应发生率比较,差异无统计学意义(χ~2=0.14,P>0.05)。结论布地奈德福莫特罗粉吸入剂联合孟鲁司特钠治疗CVA优于单用布地奈德福莫特罗粉吸入剂治疗,能显著改善肺功能,降低血浆hs-CRP指标,从而控制气道炎症反应。Objective To explore the effect of budesonide and formoterol fumarate powder for inhalation combined with montelukast on lung function and hypersensitive C-reactive protein in patients with plasma of cough variant asthma.Methods Totally 106 cases with CVA were randomly divided into observation group and control group.The patients in two groups were given budesonide and formoterol fumarate powder for inhalation,and the patients in observation group were additionally given montelukast for 2 months.The changes of lung function and hs-CRP level in two groups were observed before and after treatment,and the curative effect and adverse reaction were compared as well.Results Two months after treatment,the FEV1,FVC,and PEF in both groups were significantly increased,and the hs-CRP was significantly decreased(t=2.34,2.40,2.36,3.01,3.27,3.35,2.45,3.47,P<0.05).After treatment,the FEV1,FVC,and PEF in the observation group were significantly higher than those in the control group,and the hs-CRP was significantly lower(t=2.27,2.31,2.37,2.24,P<0.05).The total clinical efficiency in observation group was significantly higher than that in control group(χ^2=6.01,P<0.05).There was no statistical difference in the incidence of adverse reaction between two groups(χ^2=0.14,P>0.05).Conclusion The budesonide and formoterol fumarate powder for inhal?ation combined with montelukast in treatment of CVA is superior to budesonide and formoterol fumarate powder for inha?lation only,which can significantly improve the lung function and reduce hs-CRP level in plasma to control the airway inflammatory response.

关 键 词：咳嗽变异性哮喘 布地奈德福莫特罗粉吸入剂 孟鲁司特钠 肺功能 超敏-C反应蛋白 

分 类 号：R562.25[医药卫生—呼吸系统]